DE69804635D1 - Verzweigte alkoxy-substituierte 2-aminopyridine als nos inhibitoren - Google Patents

Verzweigte alkoxy-substituierte 2-aminopyridine als nos inhibitoren

Info

Publication number
DE69804635D1
DE69804635D1 DE69804635T DE69804635T DE69804635D1 DE 69804635 D1 DE69804635 D1 DE 69804635D1 DE 69804635 T DE69804635 T DE 69804635T DE 69804635 T DE69804635 T DE 69804635T DE 69804635 D1 DE69804635 D1 DE 69804635D1
Authority
DE
Germany
Prior art keywords
aminopyridine
substituted
branched alkoxy
nos inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69804635T
Other languages
English (en)
Other versions
DE69804635T2 (de
Inventor
Adams Lowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE69804635D1 publication Critical patent/DE69804635D1/de
Publication of DE69804635T2 publication Critical patent/DE69804635T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69804635T 1997-08-28 1998-08-11 Verzweigte alkoxy-substituierte 2-aminopyridine als nos inhibitoren Expired - Fee Related DE69804635T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5773997P 1997-08-28 1997-08-28
PCT/IB1998/001223 WO1999011620A1 (en) 1997-08-28 1998-08-11 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors

Publications (2)

Publication Number Publication Date
DE69804635D1 true DE69804635D1 (de) 2002-05-08
DE69804635T2 DE69804635T2 (de) 2002-07-18

Family

ID=22012464

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69804635T Expired - Fee Related DE69804635T2 (de) 1997-08-28 1998-08-11 Verzweigte alkoxy-substituierte 2-aminopyridine als nos inhibitoren

Country Status (32)

Country Link
US (2) US6362195B1 (de)
EP (1) EP1007512B1 (de)
JP (1) JP3441714B2 (de)
CN (1) CN1268122A (de)
AP (1) AP9801331A0 (de)
AR (1) AR016644A1 (de)
AT (1) ATE215532T1 (de)
AU (1) AU8458698A (de)
BR (1) BR9811921A (de)
CA (1) CA2302436C (de)
DE (1) DE69804635T2 (de)
DK (1) DK1007512T3 (de)
EA (1) EA200000165A1 (de)
ES (1) ES2172173T3 (de)
GT (1) GT199800135A (de)
HN (1) HN1998000125A (de)
HR (1) HRP980476A2 (de)
HU (1) HUP0002803A2 (de)
ID (1) ID24318A (de)
IL (1) IL134302A0 (de)
IS (1) IS5342A (de)
MA (1) MA26538A1 (de)
NO (1) NO20000957D0 (de)
OA (1) OA11294A (de)
PA (1) PA8458301A1 (de)
PE (1) PE106699A1 (de)
PL (1) PL339008A1 (de)
PT (1) PT1007512E (de)
SI (1) SI1007512T1 (de)
TN (1) TNSN98157A1 (de)
WO (1) WO1999011620A1 (de)
ZA (1) ZA987788B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
SK1702001A3 (en) * 1998-08-11 2003-02-04 Pfizer Prod Inc New pharmaceutical uses for NOS inhibitors
PL350219A1 (en) 1999-02-25 2002-11-18 Pfizer Prod Inc 2-aminopyridines containing fused ring substituents
EP1203095A2 (de) * 1999-07-30 2002-05-08 University College London Test zum auffinden von modulatoren der stickstoffmonoxid reduktase
WO2001009375A2 (en) * 1999-07-30 2001-02-08 University College London Inducible screen for drug discovery
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US6469172B2 (en) * 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20040077853A1 (en) * 2001-10-10 2004-04-22 Pfizer Inc. 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
WO2003092693A1 (en) * 2002-05-06 2003-11-13 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
US7919487B2 (en) * 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
MX2008014450A (es) * 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP3002279A1 (de) 2014-10-02 2016-04-06 Bayer CropScience AG Verfahren zur Herstellung von 3-(5-Aminotriazolyl)-Sulfid-Derivaten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
CA2244774C (en) * 1996-01-29 2006-10-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dihydropyridine derivatives, their preparation and their use as adenosine receptor antagonists
NZ500927A (en) 1996-03-29 2004-11-26 Pfizer 6-Phenylpyridyl-2-amine derivatives
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
IL134302A0 (en) 2001-04-30
PL339008A1 (en) 2000-12-04
ES2172173T3 (es) 2002-09-16
AR016644A1 (es) 2001-07-25
PA8458301A1 (es) 2000-05-24
OA11294A (en) 2003-10-22
CN1268122A (zh) 2000-09-27
PT1007512E (pt) 2002-07-31
AP9801331A0 (en) 2000-02-27
ZA987788B (en) 2000-02-28
DE69804635T2 (de) 2002-07-18
GT199800135A (es) 2000-02-08
ATE215532T1 (de) 2002-04-15
HN1998000125A (es) 1999-02-09
BR9811921A (pt) 2000-08-15
JP2001514252A (ja) 2001-09-11
ID24318A (id) 2000-07-13
IS5342A (is) 2000-01-14
CA2302436C (en) 2003-10-07
CA2302436A1 (en) 1999-03-11
EP1007512B1 (de) 2002-04-03
HUP0002803A2 (hu) 2001-06-28
EA200000165A1 (ru) 2000-10-30
US20020022642A1 (en) 2002-02-21
JP3441714B2 (ja) 2003-09-02
DK1007512T3 (da) 2002-07-08
EP1007512A1 (de) 2000-06-14
US6362195B1 (en) 2002-03-26
WO1999011620A1 (en) 1999-03-11
NO20000957L (no) 2000-02-25
SI1007512T1 (en) 2002-10-31
MA26538A1 (fr) 2004-12-20
AU8458698A (en) 1999-03-22
PE106699A1 (es) 1999-11-02
HRP980476A2 (en) 1999-06-30
TNSN98157A1 (fr) 2005-03-15
NO20000957D0 (no) 2000-02-25

Similar Documents

Publication Publication Date Title
DE69725465D1 (de) 6-phenylpyridyl-2-amin-derivate verwendbar als nos-inhibitoren
DE69930518D1 (de) Als antikrebsmittel verwendbare alkinyl-substituierte chinolin-2-on-derivate
DK1005446T3 (da) N-aroylphenylalaninderivater
ATE235220T1 (de) Resorcinderivate
PT1181017E (pt) Inibidores de metaloproteases
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
DE69804635D1 (de) Verzweigte alkoxy-substituierte 2-aminopyridine als nos inhibitoren
PT1194404E (pt) Inibidores de aspartil-protease
ID22380A (id) Turunan-turunan pirazol sebagai herbisida
FI973847A0 (fi) Anordning vid en skyddsanordning
DE69805807D1 (de) Mikrobiozide n-sulfonylglycin-alkynyloxyphenethylamid-derivate
DE59813430D1 (de) Perylenhydrazidimide als Carbonylderivatisierungsreagenzien
NO20001924D0 (no) Isoquinoliner som urokinase-inhibitorer
DE69841086D1 (de) 5-Deoxy-Cytidin-Derivate
FI971898A0 (fi) Anordning vid en anestesievaporator
FI970925A0 (fi) Anordning vid anestesianlaeggningar
ATE292632T1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin- derivate
FI971744A0 (fi) Anordning vid cirkulationssmoerjningssystem
DE69828796D1 (de) Hochreine verzweigte alkylsilsesquioxanflüssigkeiten
DE69828780D1 (de) Amidinocamptpthecin-derivate
NO981495D0 (no) Phenoxymetylpiperidin-derivater
DE69803018T2 (de) Abschminkmittel
DK1015447T3 (da) Piperidinylmethyloxazolidinonderivat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee